

SLRIPK MATCG-IDWKS^SVLPNCFK^GGNVNRSEAKVMEN^SK----QMNSD^{HH}R^LA^FS^DI^ST^DS^RS^VL^I 55
 AtRIPK MAVKKK^VSW^RS^LI^VG^CL^GD^PE^TL^MA^SS^KK^PK^RK^ND^VI^KK^QS^SF^QR^LS^IL^DM^SN^PS^SN^TL^S 60
 . .:.:*. .*: . :. : * : :*...*:*: *:* . * ..*
 SLRIPK SLDDLSSNAVIGSNLHVFTYEELKLI^{TS}DFSSANFLGKGGFGPVHKGFIDDKIKPGLDAQ 115
 AtRIPK --EDLS-ISLAGSDLHVFTLAE^LKVIT^QS^FS^ST^NFLGEGGFGPVHKGFIDDKLRPGLKAO 117
 :*** :: **:***** ***:**..**:*:***:*****:*****:*****:*****:***.*
 SLRIPK PVAV^KLLDLDGNQ^{GH}QEWL^TEVVFLGQLRHHHLV^KLIGYCWEEEQRLLVYEY^MMARGNLED 175
 AtRIPK PVAV^KLLDLEGLQGHREW^LTEVMFLGQLKHKNLV^KLIGYCCEEEH^RTLVYEFMP^RG^SLEN 177
 *****:* ***:*****:*****:***:***** ***: * *****:* **:* **:
 SLRIPK QLF^SRY^SSCLPWLTRIKIMVGAAGLAFLHGEEKPVIYRDFK^SNILLDSYRAK^LSDFG 235
 AtRIPK QLF^RRY^SASLPWSTRMKIAHGAAT^GLQFLHEAENPVIYRDFK^SNILLDSY^TAKLSDFG 237
 *** ***: .*** **:* ** * ** * ** * * :*****:*****:*****:*****
 SLRIPK LAKDGPEGDDTHSTRVMGTHGYAAPEYIM^TGHLTSKSDVYSFGVVLLELITGRRAMD^K 295
 AtRIPK LAKDGPEGDDTHSTRVMG^TQGYAAPEYIM^TGHLTARSDVYSFGVVLLELLTGRRSV^DDK 297
 *****:*****:*****:*****:*****:*****:*****:*****:***
 SLRIPK RPLKERILVDWARPMLRDPHKLDRIMDPRL^EGOY^STQGA^KVAAALAYQCLSHH^PRSRPT^M 355
 AtRIPK RSSREQLVDWARPMLNDPRKLSRIMDPRL^EGOY^SETGARKAATLAYQCLSHR^PKNRPCM 357
 * . :*: *****.*:*. ***** **:*.*:*****:*. ** *
 SLRIPK SNIVKILEPVLDMKDIPMGPFVYVVP^SSKPDKG^TEIGELK^TKVNDENKAGVRENEVDNAG 415
 AtRIPK SAVVSILNDLKDYNDIPMGTFY^TYTPN-TPDNKEDDGRVGNKPRKSSHHHHHQ^QQSNHP 416
 * :*.**: : * :*****.*.*. ** : : * . : . * : : : : . *
 SLRIPK ENREDGNAKQRRVGHRYKHRLKTDASVY^SD^THLYHK^TVKHERTNKLNSY 464
 AtRIPK RSSP^SPTTK^SPSP-TAK^SPRNSTENHRRTL^RNGVNS^SPLR^SEAGGERY-- 462
:*. . * .*: : : :...: * .:

S8 Fig. HopZ3 acetylates SIRIPK residues important for activity. Modifications in SIRIPK were determined *in vitro*, modifications in AtRIPK are from [1] (*in vitro* and *in planta*). Residues acetylated by HopZ3 are bold and highlighted in yellow; phosphorylation sites are underlined; known sites in AtRIPK important for activity (K122; S251/T252 which correspond to S198/T199 in PTO) [1] are circled in red; sites corresponding to T204 in PTO are circled in blue. * (asterisk) - fully conserved residues, : (colon) - conservation between groups of strongly similar properties, . (period) - conservation between groups of weakly similar properties.

References

1. Lee J, Manning AJ, Wolfgeher D, Jelenska J, Cavanaugh KA, Xu H, et al. Acetylation of an NB-LRR plant immune-effector complex suppresses immunity. *Cell Rep.* 2015;13(8):1670-82. doi: 10.1016/j.celrep.2015.10.029. PubMed PMID: 26586425.